Glimepiride + Metformin HCL
Generic Name: Glimepiride + Metformin Hydrochloride
Therapeutic Class: Oral Antidiabetic Combination (Sulfonylurea + Biguanide)
Indications
This combination is indicated for the management of Type 2 Diabetes Mellitus (T2DM) when diet, exercise, and single-agent therapy do not result in adequate glycemic control:
- Primary Indication: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
- Replacement Therapy: For patients already stabilized on separate doses of Glimepiride and Metformin.
- HbA1c Reduction: Specifically targeted for patients whose $HbA_{1c}$ remains high despite maximum tolerated doses of Metformin monotherapy.
Dosage & Administration
Dosage must be individualized based on the patient's current regimen, effectiveness, and tolerance.
- Initial Dose: Usually starts with the lowest strength (e.g., 1mg/500mg or 2mg/500mg) once daily.
- Administration: Should be taken with meals (usually the first main meal of the day) to reduce gastrointestinal side effects associated with Metformin and to prevent hypoglycemia from Glimepiride.
- Titration: The dose may be increased gradually based on blood glucose levels. The maximum daily dose of Glimepiride is 8 mg, and Metformin is 2500 mg.
- Extended Release (ER/XR): If using the XR formulation, tablets must be swallowed whole and not crushed or chewed.
Description & Pharmacokinetics
This combination leverages two different mechanisms to lower blood glucose levels synergistically.
Mechanism of Action: 1. Glimepiride (Sulfonylurea): Stimulates the release of insulin from functioning pancreatic $\beta$-cells by blocking ATP-sensitive potassium channels. It also improves the sensitivity of peripheral tissues to insulin. 2. Metformin (Biguanide): Reduces hepatic glucose production (gluconeogenesis), decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Pharmacokinetics:
Mechanism of Action: 1. Glimepiride (Sulfonylurea): Stimulates the release of insulin from functioning pancreatic $\beta$-cells by blocking ATP-sensitive potassium channels. It also improves the sensitivity of peripheral tissues to insulin. 2. Metformin (Biguanide): Reduces hepatic glucose production (gluconeogenesis), decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Pharmacokinetics:
- Absorption: Metformin absorption is slightly slowed by food, whereas Glimepiride is rapidly absorbed.
- Metabolism: Glimepiride is completely metabolized in the liver via CYP2C9; Metformin is not metabolized and is excreted unchanged.
- Elimination: Glimepiride metabolites are excreted in both urine and feces. Metformin is eliminated entirely via renal excretion.
Side Effects
- Hypoglycemia: Low blood sugar is the most significant side effect (due to Glimepiride), characterized by sweating, shakiness, and confusion.
- Gastrointestinal: Nausea, diarrhea, and metallic taste (due to Metformin). These often subside with continued use.
- Hematologic: Rarely, leukopenia, agranulocytosis, or thrombocytopenia.
- Lactic Acidosis: A very rare but serious metabolic complication associated with Metformin buildup, especially in patients with renal impairment.
- Vitamin Deficiency: Long-term Metformin use may lead to Vitamin $B_{12}$ malabsorption.
Extra Important Information: Usage Insights
- Renal Function: Kidney function (eGFR) must be checked before starting and at least annually thereafter, as Metformin is contraindicated in severe renal failure.
- Contrast Media: Treatment should be stopped 48 hours before any imaging procedure involving iodine-based contrast to prevent kidney injury.
- Alcohol: Avoid excessive alcohol, as it increases the risk of both hypoglycemia and lactic acidosis.
- Weight Gain: Glimepiride can cause slight weight gain, though Metformin's weight-neutral or weight-loss effect often balances this.
Pregnancy & Lactation
- Pregnancy: Generally not recommended. Insulin is the preferred treatment for maintaining blood glucose during pregnancy.
- Lactation: Not recommended. Glimepiride is excreted in breast milk, and Metformin also passes into milk, posing a risk of hypoglycemia to the nursing infant.
Storage
Store in a cool, dry place below 30°C. Protect from light and moisture. Keep the container tightly closed.
.png)
